Psoriatic arthritis is an inflammation of the joint and it affects people who suffer from psoriasis, the skin condition. Typically, patients develop skin lesions first and after some years, they get diagnosed with psoriatic arthritis. The condition causes discomfort and debilitating pain, and sadly, it has no known cure. However, there are some treatment options to control the symptoms and forestall extensive damage to the joints.


Psoriatic arthritis is caused by the immune system attacking healthy tissue and cells in the body. Immunosuppressants help keep the immune system under control, attacking the problem from the source. This, however, is not a cure,  it just alleviates the symptoms. Side effects of immunosuppressants include increased vulnerability to infections.


NSAIDs are anti-inflammatory drugs. They help alleviate the pain brought on by PA and reduce the inflammation. Common side effects are stomach ulcers, heart problems, and liver and kidney problems.

TNF-alpha inhibitors

The body produces TNF-alpha, an inflammatory substance, naturally. By inhibiting its production, the symptoms are suppressed. Possible side effects of this treatment include increased risk of infections, nausea, diarrhea, and hair loss.


Disease-modifying anti-rheumatic drugs (DMARDs) have proven effective at slowing the progression of PA and preventing permanent damage in the joints and the tissues. These also have side effects including severe lung infections, liver damage, and bone marrow suppression.

Clinical trials

All the medications above only offer temporary fixes, and they all come with major downsides. Pharmaceutical companies are working hard to provide a safer and more effective treatment for psoriatic arthritis. People who suffer from the condition can partake in their clinical studies for free.

If you have psoriatic arthritis and bDMARDs have not been effective in slowing down the disease, reach out to DM Clinical Research. You may be eligible to take part in a new clinical trial. Call 281-517-0550 now for any inquiries.